SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading NLNK News...
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | -0.13% | 79.15 | 1.2% | $812.67m | |
| SRPT | Sarepta Therapeutics, Inc. | 7.40% | 63.48 | 30.9% | $463.91m | |
| AMGN | Amgen Inc. | -0.45% | 170.85 | 1.1% | $458.84m | |
| BIIB | Biogen Inc. | -0.01% | 314.51 | 1.0% | $433.24m | |
| MDVN | Medivation, Inc. | 0.05% | 81.48 | 1.9% | $415.69m | |
| CELG | Celgene Corporation | -0.82% | 106.52 | 0.8% | $379.97m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.25% | 420.40 | 3.2% | $312.06m | |
| CPHD | Cepheid | -0.10% | 52.58 | 4.7% | $210.84m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.32% | 124.32 | 2.3% | $171.74m | |
| CLVS | Clovis Oncology, Inc. | -0.96% | 37.08 | 25.5% | $162.77m | |
| ILMN | Illumina, Inc. | -0.56% | 179.34 | 3.4% | $138.01m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.25% | 88.01 | 2.2% | $122.33m | |
| INCY | Incyte Corporation | 5.92% | 94.35 | 2.7% | $112.78m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.85% | 96.23 | 3.8% | $112.50m | |
| TSRO | TESARO, Inc. | -0.25% | 107.77 | 15.9% | $111.53m |
Company Profile
NewLink Genetics Corp. is a biopharmaceutical company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.